Shuttle Pharmaceuticals Holdings, Inc. Common Stock
SHPHShuttle Pharmaceuticals Holdings, Inc. (SHPH) is a biopharmaceutical company focused on developing and commercializing novel therapies for infectious diseases, particularly those caused by antibiotic-resistant bacteria. The company aims to address unmet medical needs through innovative drug discovery and development, leveraging its proprietary platform technologies.
Company News
Shuttle Pharmaceuticals has signed a non-binding letter of intent to acquire Molecule.ai, an AI-driven drug discovery platform, for $10 million. The acquisition aims to leverage advanced machine learning models to accelerate pharmaceutical research and development.
Shuttle Pharmaceuticals Holdings, Inc. (SHPH) announced the closing of a $5.75 million underwritten public offering. The company plans to use the proceeds to fund its Phase II clinical trial, marketing, and general corporate purposes.
Shuttle Pharmaceuticals has successfully dosed the first three patients in its Phase 2 clinical trial of Ropidoxuridine for the treatment of glioblastoma, a deadly brain cancer. The company has also finalized agreements with six clinical trial sites and raised additional funding to support the trial.
Shuttle Pharmaceuticals Holdings, Inc. announced the pricing of a $4.5 million public offering, with the proceeds to be used for clinical trials and general corporate purposes.
Shuttle Pharmaceuticals Holdings, Inc. announced the pricing of a $4.5 million public offering, with the proceeds to be used for clinical trials and general corporate purposes.
